Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Management is executing a three-pillar turnaround strategy focused on stabilizing the business, strengthening the balance ...

A Dosage analysis of Kentucky Derby (G1) starters identifies Emerging Market as the "gold standard" as judged by his ...

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical ...

The Virtus KAR Small-Cap Growth Fund returned -9.88% (Class I) in the quarter, underperforming the Russell 2000® Growth Index ...

Baxter (NYSE:BAX) today reported first-quarter results that came in ahead of the consensus forecast on Wall Street.

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Baxter’s latest quarterly performance highlights steady healthcare demand, evolving strategy, and its positioning within the ...

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host ...

Following established clinical guidelines, treatment typically begins with a series of six infusions over two to three weeks.

Approval ratings for Congress currently sit at an abysmal 16%, and it’s no wonder why: Last year, the federal government ...